Acurx Pharmaceuticals (NASDAQ:ACXP) Rating Lowered to “Sell” at Wall Street Zen

Acurx Pharmaceuticals (NASDAQ:ACXP) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

ACXP has been the subject of a number of other research reports. HC Wainwright restated a “buy” rating and issued a $31.00 price target on shares of Acurx Pharmaceuticals in a research note on Tuesday, September 30th. Weiss Ratings reissued a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a report on Wednesday, October 8th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $31.00.

Acurx Pharmaceuticals Stock Performance

NASDAQ:ACXP opened at $3.35 on Friday. The stock has a market cap of $7.01 million, a price-to-earnings ratio of -0.39 and a beta of -1.25. Acurx Pharmaceuticals has a one year low of $3.17 and a one year high of $25.00. The business’s 50-day simple moving average is $4.87 and its 200 day simple moving average is $6.08.

Acurx Pharmaceuticals (NASDAQ:ACXP) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($1.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.61) by $0.38. On average, equities research analysts predict that Acurx Pharmaceuticals will post -0.89 EPS for the current year.

Institutional Trading of Acurx Pharmaceuticals

An institutional investor recently bought a new position in Acurx Pharmaceuticals stock. Armistice Capital LLC purchased a new position in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 1,078,540 shares of the company’s stock, valued at approximately $551,000. Armistice Capital LLC owned about 70.13% of Acurx Pharmaceuticals at the end of the most recent quarter. Institutional investors own 11.53% of the company’s stock.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc, headquartered in King of Prussia, Pennsylvania, is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel anti‐infective therapies. The company’s research platform leverages insights into bacterial virulence regulation and quorum sensing pathways to design small-molecule candidates aimed at reducing pathogen toxicity and biofilm formation. By targeting key mechanisms of infection rather than bacterial viability alone, Acurx seeks to offer differentiated treatment options that may help address the growing challenge of antibiotic resistance.

Acurx’s lead product candidates are being developed to treat acute bacterial skin and skin structure infections (ABSSSI), including cases caused by drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA).